117 related articles for article (PubMed ID: 10919354)
1. In vivo targeting by liposomes.
Maruyama K
Biol Pharm Bull; 2000 Jul; 23(7):791-9. PubMed ID: 10919354
[TBL] [Abstract][Full Text] [Related]
2. PEG-immunoliposome.
Maruyama K
Biosci Rep; 2002 Apr; 22(2):251-66. PubMed ID: 12428903
[TBL] [Abstract][Full Text] [Related]
3. Possibility of active targeting to tumor tissues with liposomes.
Maruyama K; Ishida O; Takizawa T; Moribe K
Adv Drug Deliv Rev; 1999 Nov; 40(1-2):89-102. PubMed ID: 10837782
[TBL] [Abstract][Full Text] [Related]
4. Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies.
Maruyama K; Takizawa T; Yuda T; Kennel SJ; Huang L; Iwatsuru M
Biochim Biophys Acta; 1995 Mar; 1234(1):74-80. PubMed ID: 7880861
[TBL] [Abstract][Full Text] [Related]
5. Immunoliposomes bearing polyethyleneglycol-coupled Fab' fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo.
Maruyama K; Takahashi N; Tagawa T; Nagaike K; Iwatsuru M
FEBS Lett; 1997 Aug; 413(1):177-80. PubMed ID: 9287139
[TBL] [Abstract][Full Text] [Related]
6. Comparison of anti-EGFR-Fab' conjugated immunoliposomes modified with two different conjugation linkers for siRNa delivery in SMMC-7721 cells.
Deng L; Zhang Y; Ma L; Jing X; Ke X; Lian J; Zhao Q; Yan B; Zhang J; Yao J; Chen J
Int J Nanomedicine; 2013; 8():3271-83. PubMed ID: 24023515
[TBL] [Abstract][Full Text] [Related]
7. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.
Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D
Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319
[TBL] [Abstract][Full Text] [Related]
8. [Study on preparation and biodistribution of PEG-immunoliposomes with active carboxylic terminals].
Zhang YF; Xie SS; Hou XP; Gao X; Zhang S; Chen ZS
Yao Xue Xue Bao; 2000 Nov; 35(11):854-9. PubMed ID: 11218866
[TBL] [Abstract][Full Text] [Related]
9. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
[TBL] [Abstract][Full Text] [Related]
10. Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo.
Ishida O; Maruyama K; Tanahashi H; Iwatsuru M; Sasaki K; Eriguchi M; Yanagie H
Pharm Res; 2001 Jul; 18(7):1042-8. PubMed ID: 11496943
[TBL] [Abstract][Full Text] [Related]
11. Improvement of therapeutic effect by using Fab' fragment in the treatment of carcinoembryonic antigen-positive human solid tumors with adriamycin-entrapped immunoliposomes.
Uyama I; Kumai K; Yasuda T; Tagawa T; Ishibiki K; Kitajima M; Tadakuma T
Jpn J Cancer Res; 1994 Apr; 85(4):434-40. PubMed ID: 8200855
[TBL] [Abstract][Full Text] [Related]
12. Characterization of in vivo immunoliposome targeting to pulmonary endothelium.
Maruyama K; Holmberg E; Kennel SJ; Klibanov A; Torchilin VP; Huang L
J Pharm Sci; 1990 Nov; 79(11):978-84. PubMed ID: 2292774
[TBL] [Abstract][Full Text] [Related]
13. Characterization of organ-specific immunoliposomes for delivery of 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine in a mouse lung-metastasis model.
Mori A; Kennel SJ; van Borssum Waalkes M; Scherphof GL; Huang L
Cancer Chemother Pharmacol; 1995; 35(6):447-56. PubMed ID: 7882453
[TBL] [Abstract][Full Text] [Related]
14. Lipid composition is important for highly efficient target binding and retention of immunoliposomes.
Maruyama K; Kennel SJ; Huang L
Proc Natl Acad Sci U S A; 1990 Aug; 87(15):5744-8. PubMed ID: 2377612
[TBL] [Abstract][Full Text] [Related]
15. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice.
Sugano M; Egilmez NK; Yokota SJ; Chen FA; Harding J; Huang SK; Bankert RB
Cancer Res; 2000 Dec; 60(24):6942-9. PubMed ID: 11156394
[TBL] [Abstract][Full Text] [Related]
16. Preparation and Characterization of Trastuzumab Fab-Conjugated Liposomes (Immunoliposomes).
Jin S; Li H; Xu Y
Methods Mol Biol; 2023; 2622():197-205. PubMed ID: 36781762
[TBL] [Abstract][Full Text] [Related]
17. Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol).
Maruyama K; Yuda T; Okamoto A; Kojima S; Suginaka A; Iwatsuru M
Biochim Biophys Acta; 1992 Sep; 1128(1):44-9. PubMed ID: 1390877
[TBL] [Abstract][Full Text] [Related]
18. [PEG-liposome in DDS and clinical studies].
Maruyama K
Nihon Rinsho; 1998 Mar; 56(3):632-7. PubMed ID: 9549348
[TBL] [Abstract][Full Text] [Related]
19. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects.
Maruyama K
Adv Drug Deliv Rev; 2011 Mar; 63(3):161-9. PubMed ID: 20869415
[TBL] [Abstract][Full Text] [Related]
20. EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells.
Mamot C; Ritschard R; Küng W; Park JW; Herrmann R; Rochlitz CF
J Drug Target; 2006 May; 14(4):215-23. PubMed ID: 16777680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
